Potential role of lymphotoxin-alpha (tumor necrosis factor-beta) in the development of schizophrenia

Medical Hypotheses

Volumn 68, Issue 6, 2007, Pages 1359-1362

  Pae, Chi Un ^a,b  

^a The Catholic University of Korea   (South Korea)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; DOPAMINE; GLUTAMIC ACID; INTERLEUKIN 6; LYMPHOTOXIN; MESSENGER RNA; N METHYL DEXTRO ASPARTIC ACID; NERVE GROWTH FACTOR; NITRIC OXIDE; NORADRENALIN; TUMOR NECROSIS FACTOR ALPHA;

ANTIBODY RESPONSE; ARTICLE; BRAIN FUNCTION; CENTRAL NERVOUS SYSTEM; CHROMOSOME 6; CYTOKINE PRODUCTION; DISEASE PREDISPOSITION; GENE LOCUS; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNE SYSTEM; IMMUNOGENETICS; IMMUNOMODULATION; INTRAUTERINE INFECTION; MENTAL DISEASE; NEUROPROTECTION; NEUROTRANSMISSION; NEUROTRANSMITTER RELEASE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA; TOXOPLASMOSIS;

ALLELES; CHROMOSOMES, HUMAN, PAIR 6; HUMANS; LYMPHOTOXIN-ALPHA; MODELS, IMMUNOLOGICAL; POLYMORPHISM, GENETIC; SCHIZOPHRENIA;

EID: 33947727197     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2006.10.023     Document Type: Article

References (34)

1. Naudin J., Mege J.L., Azorin J.M., and Dassa D. Elevated circulating levels of IL-6 in schizophrenia. Schizophr Res 20 (1996) 269-273
2. Schultz S.K., and Andreasen N.C. Schizophrenia. Lancet 353 (1999) 1425-1430
3. Strous R.D., and Shoenfeld Y. Schizophrenia, autoimmunity and immune system dysregulation: a comprehensive model updated and revisited. J Autoimmun (2006)
4. DeLisi L.E., Boccio A.M., Riordan H., Hoff A.L., Dorfman A., McClelland J., et al. Familial thyroid disease and delayed language development in first admission patients with schizophrenia. Psychiatry Res 38 (1991) 39-50
5. Gilmore J.H., and Jarskog L.F. Exposure to infection and brain development: cytokines in the pathogenesis of schizophrenia. Schizophr Res 24 (1997) 365-367
6. Brown A.S. Prenatal infection as a risk factor for schizophrenia. Schizophr Bull 32 (2006) 200-202
7. Shirts B.H., Bamne M., Kim J.J., Talkowski M., Wood J., Yolken R., et al. A comprehensive genetic association and functional study of TNF in schizophrenia risk. Schizophr Res 83 (2006) 7-13
8. Buka S.L., Tsuang M.T., Torrey E.F., Klebanoff M.A., Wagner R.L., and Yolken R.H. Maternal cytokine levels during pregnancy and adult psychosis. Brain Behav Immun 15 (2001) 411-420
9. Marx C.E., Jarskog L.F., Lauder J.M., Lieberman J.A., and Gilmore J.H. Cytokine effects on cortical neuron MAP-2 immunoreactivity: implications for schizophrenia. Biol Psychiatry 50 (2001) 743-749
10. Urakubo A., Jarskog L.F., Lieberman J.A., and Gilmore J.H. Prenatal exposure to maternal infection alters cytokine expression in the placenta, amniotic fluid, and fetal brain. Schizophr Res 47 (2001) 27-36
11. Ashdown H., Dumont Y., Ng M., Poole S., Boksa P., and Luheshi G.N. The role of cytokines in mediating effects of prenatal infection on the fetus: implications for schizophrenia. Mol Psychiatry 11 (2006) 47-55
12. Jarskog L.F., Xiao H., Wilkie M.B., Lauder J.M., and Gilmore J.H. Cytokine regulation of embryonic rat dopamine and serotonin neuronal survival in vitro. Int J Dev Neurosci 15 (1997) 711-716
13. Libert C., Wielockx B., Grijalba B., Van Molle W., Kremmer E., Colten H.R., et al. The role of complement activation in tumour necrosis factor-induced lethal hepatitis. Cytokine 11 (1999) 617-625
14. Cazzullo C.L., Scarone S., Grassi B., Vismara C., Trabattoni D., Clerici M., et al. Cytokines production in chronic schizophrenia patients with or without paranoid behaviour. Prog Neuropsychopharmacol Biol Psychiatry 22 (1998) 947-957
15. Cazzullo C.L., Sacchetti E., Galluzzo A., Panariello A., Adorni A., Pegoraro M., et al. Cytokine profiles in schizophrenic patients treated with risperidone: a 3-month follow-up study. Prog Neuropsychopharmacol Biol Psychiatry 26 (2002) 33-39
16. Pae C.U., Yoon C.H., Kim T.S., Kim J.J., Park S.H., Lee C.U., et al. Antipsychotic treatment may alter T-helper (TH) 2 arm cytokines. Int Immunopharmacol 6 (2006) 666-671
17. Goldbach J.M., Roth J., Storr B., and Zeisberger E. Changes of abdominal temperature and circulating levels of cortisol and interleukin-6 in response to intra-arterial infusions of tumor necrosis factor-alpha or tumor necrosis factor-beta in guinea pigs. Eur J Pharmacol 334 (1997) 249-254
18. McQuaid S., Campbell R., Isserte S., and Cosby S.L. Leukaemia inhibitory factor mRNA is expressed in the brains of patients with subacute sclerosing panencephalitis. J Neuroimmunol 77 (1997) 57-62
19. Christensen J., Holcomb J., and Garver D.L. State-related changes in cerebral white matter may underlie psychosis exacerbation. Psychiatry Res 130 (2004) 71-78
20. Schluter D., Kwok L.Y., Lutjen S., Soltek S., Hoffmann S., Korner H., et al. Both lymphotoxin-alpha and TNF are crucial for control of Toxoplasma gondii in the central nervous system. J Immunol 170 (2003) 6172-6182
21. Smith R.S., and Maes M. The macrophage-T-lymphocyte theory of schizophrenia: additional evidence. Med Hypotheses 45 (1995) 135-141
22. Cheng B., Christakos S., and Mattson M.P. Tumor necrosis factors protect neurons against metabolic-excitotoxic insults and promote maintenance of calcium homeostasis. Neuron 12 (1994) 139-153
23. Pearce B.D. Schizophrenia and viral infection during neurodevelopment: a focus on mechanisms. Mol Psychiatry 6 (2001) 634-646
24. Hattori A., Tanaka E., Murase K., Ishida N., Chatani Y., Tsujimoto M., et al. Tumor necrosis factor stimulates the synthesis and secretion of biologically active nerve growth factor in non-neuronal cells. J Biol Chem 268 (1993) 2577-2582
25. Jennings C.A., Cluderay J.E., Gartlon J., Cilia J., Lloyd A., Jones D.N., et al. The effects of ziprasidone on regional c-Fos expression in the rat forebrain. Psychopharmacology (Berl) 184 (2006) 13-20
26. Wright P., Nimgaonkar V.L., Donaldson P.T., and Murray R.M. Schizophrenia and HLA: a review. Schizophr Res 47 (2001) 1-12
27. Spies T., Morton C.C., Nedospasov S.A., Fiers W., Pious D., and Strominger J.L. Genes for the tumor necrosis factors alpha and beta are linked to the human major histocompatibility complex. Proc Natl Acad Sci USA 83 (1986) 8699-8702
28. Campbell R.D., and Trowsdale J. Map of the human MHC. Immunol Today 14 (1993) 349-352
29. Keso T., Perola M., Laippala P., Ilveskoski E., Kunnas T.A., Mikkelsson J., et al. Polymorphisms within the tumor necrosis factor locus and prevalence of coronary artery disease in middle-aged men. Atherosclerosis 154 (2001) 691-697
30. Messer G., Spengler U., Jung M.C., Honold G., Blomer K., Pape G.R., et al. Polymorphic structure of the tumor necrosis factor (TNF) locus: an NcoI polymorphism in the first intron of the human TNF-beta gene correlates with a variant amino acid in position 26 and a reduced level of TNF-beta production. J Exp Med 173 (1991) 209-219
31. Abraham L.J., French M.A., and Dawkins R.L. Polymorphic MHC ancestral haplotypes affect the activity of tumour necrosis factor-alpha. Clin Exp Immunol 92 (1993) 14-18
32. Molvig J., Pociot F., Baek L., Worsaae H., Dall Wogensen L., Christensen P., et al. Monocyte function in IDDM patients and healthy individuals. Scand J Immunol 32 (1990) 297-311
33. Stuber F., Petersen M., Bokelmann F., and Schade U. A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-alpha concentrations and outcome of patients with severe sepsis. Crit Care Med 24 (1996) 381-384
34. Jun T.Y., Pae C.U., Chae J.H., Bahk W.M., Kim K.S., Han H., et al. TNFB polymorphism may be associated with schizophrenia in the Korean population. Schizophr Res 61 (2003) 39-45